FRUSICA-2 Ph 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint in Advanced RCC in China March 26, 2025
SGO 2025: Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer March 26, 2025
Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
SGO 2025: ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients March 18, 2025
Actimab-A + CLAG-M Trial Results in Patients with R/R AML published in the Journal Leukemia March 18, 2025
JAMA Study suggests that Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression March 18, 2025
SGO 2025: Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC announced March 18, 2025
SGO 2025: Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer Presented March 18, 2025
SGO 2025: Rinatabart Sesutecan (Rina-S) Shows Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer March 18, 2025
Ph 3 Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab published in The Lancet March 11, 2025
ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial March 11, 2025
Promising Early Efficacy and Safety Data for AVA6000 in the Ph 1a Dose Escalation and Ongoing Enrollment in the Ph 1b Expansion Cohorts Announced March 11, 2025
Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers March 11, 2025
Positive Topline Ph 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Grade 1/2 SSTR+ve GEP-NETs Presented March 11, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
Camizestrant demonstrated highly statistically significant improvement in PFS in 1L advanced HR+ve breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Ph 3 trial March 4, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
Additional Positive Data from Ph 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors Presented March 4, 2025
Positive Clinical Data Demonstrating Survival and Clinical Responses with triple combination of Versamune® HPV, PDS01ADC and a PD-L1 inhibitor in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology March 4, 2025
Neoadjuvant Opdivo® + Chemo Demonstrate Statistically Significant and Clinically Meaningful OS in Resectable NSCLC February 25, 2025
Translational Data Announced from Ph 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 25, 2025
